Smoking Cessation Treatment Market Size was ~USD 1800 Million in 2022, estimated DelveInsight

"Smoking Cessation Therapies such as Bupropion, Zonisamide, Cytisinicline, Nicoderm, Varenicline, and others"

The Smoking Cessation Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Smoking Cessation therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight's "Smoking Cessation Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Smoking Cessation Market Report

*
The increase in market size is a direct consequence of expected approval of emerging therapies and increasing diagnosed prevalent population of Smoking Cessation in the 7MM.

*
The leading Smoking Cessation Companies such as Rose Research Center LLC, Achieve Life Sciences, NFL Biosciences SAS, and others.

*
Promising Smoking Cessation Therapies such as Bupropion, Zonisamide, Cytisinicline, Nicoderm, Varenicline, and others.

*
As per DelveInsight's assessment, the diagnosed prevalence of smoking is higher in males as compared to females.

*
As per DelveInsight analysts, the total diagnosed prevalent cases of Smoking Cessation in the 7MM was 50,899,152 in 2022.

*
August 2024:- Rose Research Center, LLC- combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline information on the use of combustible cigarettes.

Gain a competitive edge in the Smoking Cessation Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Smoking Cessation Treatment Drugs [https://www.delveinsight.com/sample-request/smoking-cessation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Smoking Cessation Treatment Market

There are effective treatments that support tobacco cessation, including both behavioral therapies and medications. There are 89 distinct products and services available today for smoking cessation, alongside 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy (NRT) in the form of a transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline. Nortriptyline and clonidine have been shown in clinical trials to promote smoking cessation, but regulatory authorities have not approved them for this purpose.

Smoking Cessation Emerging Drugs Profile

*
AXS-05: Axsome Therapeutics

Smoking Cessation Marketed Drugs

*
Varenicline (Chantix/Champix): Pfizer

Discover key developments and opportunities in the Smoking Cessation Market. Click here to learn more from DelveInsight's latest report @ Smoking Cessation Market Size [https://www.delveinsight.com/sample-request/smoking-cessation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Smoking Cessation Drugs and Companies

*
Bupropion: Rose Research Center LLC

*
Cytisinicline: Achieve Life Sciences

*
NFL-101: NFL Biosciences SAS

Smoking Cessation Drugs Uptake

*
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, in clinical development for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and smoking cessation. The drug consists of dextromethorphan (DM) and bupropion and utilizes Axsome's metabolic inhibition technology. The DM component of AXS-05 is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and an inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor. Both components are nicotinic acetylcholine receptor antagonists and have demonstrated anti-inflammatory properties. The Phase II clinical results of the AXS-05 shows a 25% greater reduction in average cigarettes per day for AXS-05 versus bupropion. AXS-05 is currently being developed for the treatment of major depressive disorder (MDD), Alzheimer's disease agitation, and smoking cessation.

*
Cytisinicline (also known as cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve Life Sciences, Inc. on January, 2022 announced that the last study follow-up visit for the last subject enrolled in the ORCA-2 Phase III trial occurred in late December 2021. The ORCA-2 trial is the first Phase III trial in Achieve's ORCA Program, designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken three times daily (TID) for either 6 or 12 weeks, compared with placebo. Topline data regarding the primary results are expected in the second quarter of 2022.

*
NFL-101, NFL-101 is a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. NFL-101 is delivered via two simple subcutaneous injections, administered one week apart at a Target Quit Date, making patient compliance a breeze. Two additional, optional injections are made available to patients still not abstinent at month three and six. Preclinical studies' results have been approved by the French Agency for Drug Safety (ANSM). A Phase I/II clinical trial (CESTO, NCT02521701) that reported NFL-101 data in 2017 and that was implemented at the Montpellier Cancer Institute (ICM) confirmed safety and efficacy in smokers willing and trying to quit, in terms of total cessation at twelve months as well as reduction without compensatory over-smoking. A second patent was filed in 2016. A Phase II/III clinical study has been approved in France where it is currently ongoing

Smoking Cessation Market Insights

The use of nicotine sustains tobacco addiction, which in turn causes devastating health problems, including heart disease, lung disease, and cancer. Smoking harms almost every organ of the body. Quitting smoking at any age leads to significant reductions in the risks associated with smoking, and the vast majority of smokers in the United States indicate an interest in quitting.

Download DelveInsight's Smoking Cessation Market report today and stay ahead in this rapidly evolving field. @ Smoking Cessation Clinical Trials [https://www.delveinsight.com/sample-request/smoking-cessation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Smoking Cessation Market Report

*
Coverage- 7MM

*
Smoking Cessation Companies- Rose Research Center LLC, Achieve Life Sciences, NFL Biosciences SAS, and others.

*
Smoking Cessation Therapies- Bupropion, Zonisamide, Cytisinicline, Nicoderm, Varenicline, and others.

*
Smoking Cessation Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Smoking Cessation Unmet Needs, KOL's views, Analyst's views, Smoking Cessation Market Access and Reimbursement

Download the report to understand which factors are driving Smoking Cessation market trends @ Smoking Cessation Market Trends [https://www.delveinsight.com/sample-request/smoking-cessation-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Executive Summary of Smoking Cessation

3. Competitive Intelligence Analysis for Smoking Cessation

4. Smoking Cessation: Market Overview at a Glance

5. Smoking Cessation: Disease Background and Overview

6. Patient Journey

7. Smoking Cessation Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Smoking Cessation Unmet Needs

10. Key Endpoints of Smoking Cessation Treatment

11. Smoking Cessation Marketed Products

12. Smoking Cessation Emerging Therapies

13. Smoking Cessation: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Smoking Cessation

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=smoking-cessation-treatment-market-size-was-usd-1800-million-in-2022-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.